Advertisement

AAPS PharmSciTech

, 20:43 | Cite as

Drug-Phospholipid Complex—a Go Through Strategy for Enhanced Oral Bioavailability

  • Kaushik Kuche
  • Nallamothu Bhargavi
  • Chander Parkash Dora
  • Sanyog JainEmail author
Review Article Theme: Lipid-Based Drug Delivery Strategies for Oral Drug Delivery
  • 58 Downloads
Part of the following topical collections:
  1. Theme: Lipid-Based Drug Delivery Strategies for Oral Drug Delivery

Abstract

Among many, the oral route of delivery is considered to be the most favorable route with the highest patient compliance. The main issue with oral delivery is the environmental vulnerability of gastro intestinal tract (G.I.T). The bioavailability could further decrease when drug has poor aqueous solubility and permeability through biological membrane. This drawback could be resolved by employing drug-phospholipid complex strategy, as they utilize mechanism which is similar to the absorption mechanism of nutritional constituents form G.I.T. The drug-phospholipid complexes are considered ideal for oral delivery as they are biodegradable and non-toxic, which enable them to be employed as solubilizer, emulsifier, and as a matrix forming excipient for dugs with poor solubility and/or permeability. The present review compiles the basic know how about the phospholipids and the mechanism through which it improves the bioavailability of drugs. Further, it also compiles the crucial formulation aspects and methods of preparations of drug-phospholipid complex along with its physical and in silico characterization techniques. The increase in number of recent reports involving the utilization of drug-phospholipid complex to improve oral bioavailability of drugs thus explains how vital the strategy is for a successful oral delivery.

KEY WORDS

oral bioavailability phospholipid drug-phospholipid complex characterization 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–23.PubMedGoogle Scholar
  2. 2.
    Kuche K, Maheshwari R, Tambe V, Mak K-K, Jogi H, Raval N, et al. Carbon nanotubes (CNTs) based advanced dermal therapeutics: current trends and future potential. Nanoscale. 2018;10(19):8911–37.PubMedGoogle Scholar
  3. 3.
    Yan C, Gu J, Lv Y, Shi W, Jing H. Improved intestinal absorption of water-soluble drugs by acetylation of G2 PAMAM dendrimer nanocomplexes in rat. Drug Deliv Transl Res. 2017;7(3):408–15.Google Scholar
  4. 4.
    Kirtane AR, Narayan P, Liu G, Panyam J. Polymer-surfactant nanoparticles for improving oral bioavailability of doxorubicin. J Pharm Investig. 2017;47(1):65–73.Google Scholar
  5. 5.
    Pandey SC, Kaur R, Gangadharapp H, Sachin J. Self-emulsifying drug delivery system: a review. RJPT. 2018;1(4):313–23.Google Scholar
  6. 6.
    Vilas PC, Gujarathi NA, Rane BR, Pawar SP. A Review on self microemulsifying drug delivery system. Pharma Sci Monit. 2013;4(1):3628–48.Google Scholar
  7. 7.
    Andonova V, Peneva P. Characterization methods for solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). Curr Pharm Des. 2017;23(43):6630–42.Google Scholar
  8. 8.
    Semalty A, Semalty M, Rawat BS, Singh D, Rawat M. Pharmacosomes: the lipid-based new drug delivery system. Expert Opin Drug Deliv. 2009;6(6):599–612.PubMedGoogle Scholar
  9. 9.
    J-n Y, Zhu Y, Wang L, Peng M, S-s T, Cao X, et al. Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles. Acta Pharmacol Sin. 2010;31(6):759.Google Scholar
  10. 10.
    Gnananath K, Nataraj KS, Rao BG. Phospholipid complex technique for superior bioavailability of Phytoconstituents. Adv Pharm Bull. 2017;7(1):35–42.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Singh RP, Gangadharappa H, Mruthunjaya K. Phospholipids: unique carriers for drug delivery systems. J Drug Deliv Sci Technol. 2017;39:166–79.Google Scholar
  12. 12.
    Marsh D. General features of phospholipid phase transitions. Chem Phys Lipids. 1991;57(2–3):109–20.PubMedGoogle Scholar
  13. 13.
    Seimiya T, Ohki S. Ionic structure of phospholipid membranes, and binding of calcium ions. Biochim Biophys Acta (BBA)-Biomembr. 1973;298(3):546–61.Google Scholar
  14. 14.
    Sosenko IR, Innis SM, Frank L. Intralipid increases lung polyunsaturated fatty acids and protects newborn rats from oxygen toxicity. Pediatr Res. 1991;30(5):413–7.PubMedGoogle Scholar
  15. 15.
    de Boer JF, Kuipers F, Groen AK. Cholesterol transport revisited: A new Turbo mechanism to drive cholesterol excretion. Trends Endocrin Met. 2017;29(2):123–33.Google Scholar
  16. 16.
    Mills PC, Chen Y, Hills YC, Hills BA. Comparison of surfactant lipids between pleural and pulmonary lining fluids. Pulm Pharmacol Ther. 2006;19(4):292–6.Google Scholar
  17. 17.
    Cevc G. Phospholipids handbook: CRC press; 1993.Google Scholar
  18. 18.
    Li J, Wang X, Zhang T, Wang C, Huang Z, Luo X, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci. 2015;10(2):81–98.Google Scholar
  19. 19.
    Intermolecular JI. Surface forces. San Diego: Academic press; 1992.Google Scholar
  20. 20.
    McMahon HT, Gallop JL. Membrane curvature and mechanisms of dynamic cell membrane remodelling. Nature. 2005;438(7068):590–6.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Phillips R, Theriot J, Kondev J, Garcia H. Physical biology of the cell: Garland. Science. 2012.Google Scholar
  22. 22.
    Sharma S, Roy RK. Phytosomes: an emerging technology. Int J Pharm Res Dev. 2010;2(5):1–7.Google Scholar
  23. 23.
    Kapoor B, Gupta R, Singh SK, Gulati M, Singh S. Prodrugs, phospholipids and vesicular delivery-an effective triumvirate of pharmacosomes. Adv Colloid Interf Sci. 2018;253:35–65.Google Scholar
  24. 24.
    Carey MC, Small DM. The characteristics of mixed micellar solutions with particular reference to bile. Am J Med. 1970;49(5):590–608.PubMedGoogle Scholar
  25. 25.
    Gangwar M, Singh R, Goel R, Nath G. Recent advances in various emerging vescicular systems: an overview. Asian Pac J Trop Biomed. 2012;2(2):S1176–S88.Google Scholar
  26. 26.
    Bhingare U, Khadabadi S, Shinde N. Pharmacosomes: A novel drug delivery system. Int J. 2014;3(1):14–20.Google Scholar
  27. 27.
    Gavhane YN, Yadav AV. Loss of orally administered drugs in GI tract. Saudi Pharm J. 2012;20(4):331–44.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Jena SK, Singh C, Dora CP, Suresh S. Development of tamoxifen-phospholipid complex: novel approach for improving solubility and bioavailability. Int J Pharm. 2014;473(1–2):1–9.PubMedGoogle Scholar
  29. 29.
    van Hoogevest P. Review–an update on the use of oral phospholipid excipients. Eur J Pharm Sci. 2017;108:1–12.PubMedGoogle Scholar
  30. 30.
    Chaudhri O, Small C, Bloom S. Gastrointestinal hormones regulating appetite. Phil Trans R Soc London B: Biol Sci. 2006;361(1471):1187–209.Google Scholar
  31. 31.
    Marieb EN, Hoehn K. Human anatomy and physiology. 8e éd ed. San Francisco: Benjamin Cummings; 2010.Google Scholar
  32. 32.
    Kossena GA, Charman WN, Wilson CG, O’Mahony B, Lindsay B, Hempenstall JM, et al. Low dose lipid formulations: effects on gastric emptying and biliary secretion. Pharm Res. 2007;24(11):2084–96.PubMedGoogle Scholar
  33. 33.
    Higgins J, Fielding C. Lipoprotein lipase. Mechanism of formation of triglyceride-rich remnant particles from very low density lipoproteins and chylomicrons. Biochemistry. 1975;14(11):2288–93.PubMedGoogle Scholar
  34. 34.
    Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv. 2011;8(11):1407–24.PubMedGoogle Scholar
  35. 35.
    Nestel P, Havel R, Bezman A. Sites of initial removal of chylomicron triglyceride fatty acids from the blood. J Clin Invest. 1962;41(10):1915–21.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Semalty A, Semalty M, Singh D, Rawat M. Phyto-phospholipid complex of catechin in value added herbal drug delivery. J Incl Phenom Macrocycl Chem. 2012;73(1–4):377–86.Google Scholar
  37. 37.
    Alexander A, Ajazuddin S, Verma T, Swarna MJ, Patel S. Mechanism responsible for mucoadhesion of mucoadhesive drug delivery system: a review. Int J Appl Biol Pharm Technol. 2011;2(1):434–45.Google Scholar
  38. 38.
    Behra A, Giri TK, Tripathi DK, Ajazuddin AA. An exhaustive review on recent advancement in pharmaceutical bioadhesive used for systemic drug delivery through oral mucosa for achieving maximum pharmacological response and effect. Int J Pharmacol. 2012;8(5):283–305.Google Scholar
  39. 39.
    Afanas’eva YG, Fakhretdinova E, Spirikhin L, Nasibullin R. Mechanism of interaction of certain flavonoids with phosphatidylcholine of cellular membranes. Pharm Chem J. 2007;41(7):354–6.Google Scholar
  40. 40.
    Li N, Ye Y, Yang M, Jiang X, Ma J. Pharmacokinetics of baicalin-phospholipid complex in rat plasma and brain tissues after intranasal and intravenous administration. Die Pharmazie-an international. J Pharm Sci. 2011;66(5):374–7.Google Scholar
  41. 41.
    Yue P-F, Yuan H-L, Li X-Y, Yang M, Zhu W-F. Process optimization, characterization and evaluation in vivo of oxymatrine–phospholipid complex. Int J Pharm. 2010;387(1–2):139–46.PubMedGoogle Scholar
  42. 42.
    Maryana W, Rachmawati H, Mudhakir D. Formation of Phytosome containing Silymarin using thin layer-hydration technique aimed for Oral delivery. Mater Today Proc. 2016;3(3):855–66.Google Scholar
  43. 43.
    Qin X, Yang Y, T-t F, Gong T, X-n Z, Huang Y. Preparation, characterization and in vivo evaluation of bergenin-phospholipid complex. Acta Pharmacol Sin. 2010;31(1):127–36.PubMedGoogle Scholar
  44. 44.
    Guo B, Liu H, Li Y, Zhao J, Yang D, Wang X, et al. Application of phospholipid complex technique to improve the dissolution and pharmacokinetic of probucol by solvent-evaporation and co-grinding methods. Int J Pharm. 2014;474(1–2):50–6.PubMedGoogle Scholar
  45. 45.
    Sikarwar MS, Sharma S, Jain AK, Parial S. Preparation, characterization and evaluation of marsupsin–phospholipid complex. AAPS PharmSciTech. 2008;9(1):129–37.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Li Y, Yang D-J, Chen S-L, Chen S-B, AS-C C. Comparative physicochemical characterization of phospholipids complex of puerarin formulated by conventional and supercritical methods. Pharm Res. 2008;25(3):563–77.PubMedGoogle Scholar
  47. 47.
    Dora CP, Kushwah V, Katiyar SS, Kumar P, Pillay V, Suresh S, et al. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid. Int J Pharm. 2017;534(1–2):1–13.PubMedGoogle Scholar
  48. 48.
    Cui F, Shi K, Zhang L, Tao A, Kawashima Y. Biodegradable nanoparticles loaded with insulin–phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J Control Release. 2006;114(2):242–50.PubMedGoogle Scholar
  49. 49.
    Murugan V, Mukherjee K, Maiti K, Mukherjee PK. Enhanced oral bioavailability and antioxidant profile of ellagic acid by phospholipids. J Agric Food Chem. 2009;57(11):4559–65.PubMedGoogle Scholar
  50. 50.
    Dora CP, Kushwah V, Katiyar SS, Kumar P, Pillay V, Suresh S, et al. Improved metabolic stability and therapeutic efficacy of a novel molecular gemcitabine phospholipid complex. Int J Pharm. 2017;530(1–2):113–27.PubMedGoogle Scholar
  51. 51.
    Kumar P, Choonara YE, Pillay V. In silico affinity profiling of neuroactive polyphenols for post-traumatic calpain inactivation: a molecular docking and atomistic simulation sensitivity analysis. Molecules. 2014;20(1):135–68.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Larkin P. Infrared and Raman spectroscopy: principles and spectral interpretation. Amsterdam: Elsevier; 2017.Google Scholar
  53. 53.
    Singh C, Bhatt TD, Gill MS, Suresh S. Novel rifampicin–phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation. Int J Pharm. 2014;460(1–2):220–7.PubMedGoogle Scholar
  54. 54.
    Rajan S, Kang S-Y, Gutowsky HS, Oldfield E. Phosphorus nuclear magnetic resonance study of membrane structure. Interactions of lipids with protein, polypeptide, and cholesterol. J Biol Chem. 1981;256(3):1160–6.PubMedGoogle Scholar
  55. 55.
    Jin Y, Wunderlich B. Single-run heat capacity measurement by DSC: principle, experimental and data analysis. Thermochim Acta. 1993;226:155–61.Google Scholar
  56. 56.
    Chandrasekaran B, Abed SN, Al-Attraqchi O, Kuche K, Tekade RK. Computer-aided prediction of pharmacokinetic (ADMET) properties. In: Dosage Form Design Parameters. Amsterdam: Elsevier; 2018. p. 731–55.Google Scholar
  57. 57.
    Ngwuluka NC, Choonara YE, Kumar P, du Toit LC, Khan RA, Pillay V. A novel pH-responsive interpolyelectrolyte hydrogel complex for the oral delivery of levodopa. Part I. IPEC modeling and synthesis. J Biomed Mater Res A. 2015;103(3):1077–84.PubMedGoogle Scholar
  58. 58.
    Wang L, Hao Y, Liu N, Ma M, Yin Z, Zhang X. Enhance the dissolution rate and oral bioavailability of pranlukast by preparing nanosuspensions with high-pressure homogenizing method. Drug Dev Ind Pharm. 2012;38(11):1381–9.PubMedGoogle Scholar
  59. 59.
    Hao Y, Wang L, Li J, Liu N, Feng J, Zhao M, et al. Enhancement of solubility, transport across Madin-Darby canine kidney monolayers and oral absorption of pranlukast through preparation of a pranlukast-phospholipid complex. J Biomed Nanotechnol. 2015;11(3):469–77.PubMedGoogle Scholar
  60. 60.
    Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci. 1996;93(9):4001–5.PubMedGoogle Scholar
  61. 61.
    Qin L, Niu Y, Wang Y, Chen X. Combination of phospholipid complex and submicron emulsion techniques for improving Oral bioavailability and therapeutic efficacy of water-insoluble drug. Mol Pharm. 2018;15(3):1238–47.PubMedGoogle Scholar
  62. 62.
    Immordino ML, Brusa P, Rocco F, Arpicco S, Ceruti M, Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release. 2004;100(3):331–46.PubMedGoogle Scholar
  63. 63.
    Elnaggar YS, Shehata EM, Galal S, Abdallah OY. Self-emulsifying preconcentrates of daidzein–phospholipid complex: design, in vitro and in vivo appraisal. Nanomedicine. 2017;12(8):893–910.PubMedGoogle Scholar
  64. 64.
    Ma H, Chen H, Sun L, Tong L, Zhang T. Improving permeability and oral absorption of mangiferin by phospholipid complexation. Fitoterapia. 2014;93:54–61.PubMedGoogle Scholar
  65. 65.
    Zhou H, Han Y-m, Zheng Y-m, Xu X-y, Fu S-q, Wang L-I, et al. Preparative procedure of inclusion compound of mangiferin-HP-β-CD. J Chongqing Inst Technol (Nat Sci). 2009;9:011.Google Scholar
  66. 66.
    Li Y, Ren X, Lio C, Sun W, Lai K, Liu Y, et al. A chlorogenic acid-phospholipid complex ameliorates post-myocardial infarction inflammatory response mediated by mitochondrial reactive oxygen species in SAMP8 mice. Pharmacol Res. 2018;130:110–22.PubMedGoogle Scholar
  67. 67.
    Maheshwari R, Kuche KN, Advankar A, Soni N, Raval N, Sharma PA, et al. Natural Ingredients/Botanical Extracts for the Nutraceutical Industry. In: Flavors for Nutraceutical and Functional Foods. Boca Raton: CRC Press; 2018. p. 95–142.Google Scholar
  68. 68.
    Wu J-Y, Li Y-J, Han M, Hu X-B, Yang L, Wang J-M, et al. A microemulsion of puerarin–phospholipid complex for improving bioavailability: preparation, in vitro and in vivo evaluations. Drug Dev Ind Pharm. 2018;44(8):1336–41.PubMedGoogle Scholar
  69. 69.
    Ge L, He X, Zhang Y, Zhang Y, Chai F, Jiang L, et al. A dabigatran etexilate phospholipid complex nanoemulsion system for further oral bioavailability by reducing drug-leakage in the gastrointestinal tract. Nanomedicine. 2018;14(4):1455–64.Google Scholar
  70. 70.
    Pouton CW, Porter CJ. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev. 2008;60(6):625–37.PubMedGoogle Scholar
  71. 71.
    Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res. 1995;12(11):1561–72.PubMedGoogle Scholar
  72. 72.
    Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3–4):278–87.PubMedGoogle Scholar
  73. 73.
    Čerpnjak K, Zvonar A, Gašperlin M, Vrečer F. Lipid-based systems as promising approach for enhancing the bioavailability of poorly water-soluble drugs. Acta Pharma. 2013;63(4):427–45.Google Scholar
  74. 74.
    Walstra P. Principles of emulsion formation. Chem Eng Sci. 1993;48(2):333–49.Google Scholar
  75. 75.
    Ruan J, Liu J, Zhu D, Gong T, Yang F, Hao X, et al. Preparation and evaluation of self-nanoemulsified drug delivery systems (SNEDDSs) of matrine based on drug–phospholipid complex technique. Int J Pharm. 2010;386(1–2):282–90.PubMedGoogle Scholar
  76. 76.
    Wu H, Long X, Yuan F, Chen L, Pan S, Liu Y, et al. Combined use of phospholipid complexes and self-emulsifying microemulsions for improving the oral absorption of a BCS class IV compound, baicalin. Acta Pharm Sin B. 2014;4(3):217–26.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Wei D, Zhang X. Solubility of puerarin in the binary system of methanol and acetic acid solvent mixtures. Fluid Phase Equilib. 2013;339:67–71.Google Scholar
  78. 78.
    Xia H-j, Zhang Z-h, Jin X, Hu Q, Chen X-y, Jia X-b. A novel drug–phospholipid complex enriched with micelles: preparation and evaluation in vitro and in vivo. Int J Nanomedicine. 2013;8:545.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Munyendo WL, Zhang Z, Abbad S, Waddad AY, Lv H, Baraza LD, et al. Micelles of TPGS modified apigenin phospholipid complex for oral administration: preparation, in vitro and in vivo evaluation. J Biomed Nanotechnol. 2013;9(12):2034–47.PubMedGoogle Scholar
  80. 80.
    Jin X, Zhang Z-h, Sun E, Qian Q, X-b T, X-b J. Preparation of a nanoscale baohuoside I-phospholipid complex and determination of its absorption: in vivo and in vitro evaluations. Int J Nanomedicine. 2012;7:4907.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Beg S, Raza K, Kumar R, Chadha R, Katare O, Singh B. Improved intestinal lymphatic drug targeting via phospholipid complex-loaded nanolipospheres of rosuvastatin calcium. RSC Adv. 2016;6(10):8173–87.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  • Kaushik Kuche
    • 1
  • Nallamothu Bhargavi
    • 1
  • Chander Parkash Dora
    • 1
  • Sanyog Jain
    • 1
    Email author
  1. 1.Centre for Pharmaceutical Nanotechnology, Department of PharmaceuticsNational Institute of Pharmaceutical Education and Research (NIPER), S.A.S. NagarNagarIndia

Personalised recommendations